Will you offer Ibrutinib and Rituximab for untreated patients with CLL without a 17p deletion?

Shanafelt et al. recently presented results from the phase III E1912 study at ASH 2018. Will you still utilize FCR as first-line or now use Rituximab/Ibrutinib?

Answer from: Medical Oncologist at Community Practice

The ECOG 1912 study presented at ASH this week showed better OS and PFS in younger patients with ibrutinib, which was great news. I used to use FCR in these patients as it was said to have a higher rate of MRD but potentially dangerous myelo- and immunotoxicity and of course there's concerning issue...

Comments

Medical Oncologist at St Jude Heritage Medical Group
Thank you, so then who would you treat w FCR then ...

Medical Oncologist at Christie NHS Foundation Trust
Really good question. I would offer FCR in those c...

Medical Oncologist at Florida Cancer Specialists
Not sure that anticoagulation is an absolute contr...

Medical Oncologist at Christie NHS Foundation Trust
Mark, I would call it a relative contraindication ...

Medical Oncologist at Sarah Cannon Cancer Institute at Menorah Medical Center
I would still consider FCR in young fit patients w...

Please select the option that best describes you:

Will you offer Ibrutinib and Rituximab for untreated patients with CLL without a 17p deletion?

Related Questions